Silence Therapeutics (NASDAQ:SLN) Earns “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Silence Therapeutics (NASDAQ:SLN) in a research report sent to investors on Friday morning,Benzinga reports. They currently have a $75.00 target price on the stock.

Other equities research analysts have also issued research reports about the stock. Morgan Stanley reissued an “overweight” rating and set a $49.00 price objective on shares of Silence Therapeutics in a research note on Tuesday, October 8th. Chardan Capital reissued a “buy” rating and set a $55.00 price objective on shares of Silence Therapeutics in a research note on Thursday, November 14th. Finally, Jefferies Financial Group started coverage on shares of Silence Therapeutics in a research note on Tuesday, September 3rd. They set a “buy” rating and a $40.00 price objective on the stock. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Silence Therapeutics currently has a consensus rating of “Buy” and an average price target of $57.20.

Silence Therapeutics Price Performance

NASDAQ:SLN opened at $11.02 on Friday. Silence Therapeutics has a one year low of $9.22 and a one year high of $27.72. The company’s 50-day simple moving average is $17.82 and its 200 day simple moving average is $19.05. The firm has a market capitalization of $329.83 million, a P/E ratio of -7.02 and a beta of 1.30.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Values First Advisors Inc. purchased a new position in Silence Therapeutics in the third quarter worth about $56,000. Quarry LP purchased a new stake in Silence Therapeutics during the second quarter valued at approximately $114,000. SG Americas Securities LLC boosted its position in shares of Silence Therapeutics by 10.5% in the first quarter. SG Americas Securities LLC now owns 7,000 shares of the company’s stock worth $151,000 after purchasing an additional 667 shares during the period. Verition Fund Management LLC bought a new position in shares of Silence Therapeutics in the third quarter worth approximately $207,000. Finally, Custom Index Systems LLC bought a new position in shares of Silence Therapeutics in the second quarter worth approximately $282,000. 98.73% of the stock is owned by hedge funds and other institutional investors.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.